Equities research analysts predict that Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD – Get Rating) will post earnings of ($0.34) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Galmed Pharmaceuticals’ earnings. The highest EPS estimate is ($0.26) and the lowest is ($0.41). Galmed Pharmaceuticals reported earnings per share of ($0.38) in the same quarter last year, which would suggest a positive year-over-year growth rate of 10.5%. The business is expected to announce its next earnings results on Monday, January 1st.
On average, analysts expect that Galmed Pharmaceuticals will report full year earnings of ($1.37) per share for the current financial year, with EPS estimates ranging from ($1.60) to ($1.20). For the next financial year, analysts anticipate that the company will report earnings of ($1.43) per share, with EPS estimates ranging from ($1.68) to ($1.17). Zacks’ EPS calculations are an average based on a survey of analysts that follow Galmed Pharmaceuticals.
GLMD has been the topic of several research reports. Zacks Investment Research raised shares of Galmed Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, February 1st. StockNews.com began coverage on shares of Galmed Pharmaceuticals in a research note on Monday. They set a “sell” rating on the stock.
Several hedge funds and other institutional investors have recently modified their holdings of the stock. Raymond James & Associates increased its stake in shares of Galmed Pharmaceuticals by 10.5% in the third quarter. Raymond James & Associates now owns 229,640 shares of the biopharmaceutical company’s stock worth $641,000 after buying an additional 21,775 shares during the period. Morgan Stanley increased its position in Galmed Pharmaceuticals by 14.3% during the 1st quarter. Morgan Stanley now owns 185,552 shares of the biopharmaceutical company’s stock valued at $636,000 after purchasing an additional 23,200 shares during the period. Millennium Management LLC increased its position in Galmed Pharmaceuticals by 308.4% during the 4th quarter. Millennium Management LLC now owns 53,239 shares of the biopharmaceutical company’s stock valued at $97,000 after purchasing an additional 40,203 shares during the period. Virtu Financial LLC purchased a new position in Galmed Pharmaceuticals during the 4th quarter valued at $65,000. Finally, Geode Capital Management LLC increased its position in Galmed Pharmaceuticals by 36.2% during the 3rd quarter. Geode Capital Management LLC now owns 27,177 shares of the biopharmaceutical company’s stock valued at $75,000 after purchasing an additional 7,217 shares during the period. 13.48% of the stock is currently owned by institutional investors.
Galmed Pharmaceuticals Company Profile (Get Rating)
Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of oral therapy for the treatment of non-alcoholic steato-hepatitis (NASH). Its product candidate, Aramchol, is a synthetic fatty acid-bile acid conjugate molecule for the oral treatment of NASH in patients who are overweight or obese and have prediabetes or type II diabetes mellitus.
- Get a free copy of the StockNews.com research report on Galmed Pharmaceuticals (GLMD)
- Insiders Are Selling Palo Alto Networks
- Greenbrier Companies Stock has Green in its Future
- 3 Bank Stocks That Are Ready to Handle Whatever the Fed Throws at Them
- Tilray Stock Has Better Days Ahead
- Headwinds Mount For Carmax, Don’t Count On Higher Share Prices
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.